Evidence map›Paper›PMID 34819098›Full record

ArticleCancer cell international2021

IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma.

Rong Wei, Guoye Qi, Zixin Zeng, Ningning Shen, Ziyue Wang, Honghong Shen, Lifang Gao, Chen Song, Wenxia Ma, Chen Wang

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Rong Wei *Department of Pathology, The Second Hospital of ShanXi Medical University, No.382 WuYi Road, Tai Yuan, 030000, ShanXi, China.
Guoye Qi *Department of Pathology, The Basic Medical College of ShanXi Medical University, Tai Yuan, ShanXi, China.
Zixin Zeng *Department of Pathology, The Basic Medical College of ShanXi Medical University, Tai Yuan, ShanXi, China.
Ningning ShenDepartment of Pathology, The Second Hospital of ShanXi Medical University, No.382 WuYi Road, Tai Yuan, 030000, ShanXi, China.
Ziyue WangDepartment of Pathology, The Basic Medical College of ShanXi Medical University, Tai Yuan, ShanXi, China.
Honghong ShenDepartment of Pathology, The Second Hospital of ShanXi Medical University, No.382 WuYi Road, Tai Yuan, 030000, ShanXi, China.
Lifang GaoDepartment of Pathology, The Second Hospital of ShanXi Medical University, No.382 WuYi Road, Tai Yuan, 030000, ShanXi, China.
Chen SongDepartment of Pathology, The Second Hospital of ShanXi Medical University, No.382 WuYi Road, Tai Yuan, 030000, ShanXi, China.
Wenxia MaDepartment of Pathology, The Second Hospital of ShanXi Medical University, No.382 WuYi Road, Tai Yuan, 030000, ShanXi, China. mawenxia@sxmu.edu.cn.
Chen WangDepartment of Pathology, The Second Hospital of ShanXi Medical University, No.382 WuYi Road, Tai Yuan, 030000, ShanXi, China. wangchen@sxmu.edu.cn.ORCID http://orcid.org/0000-0002-4919-9677
Shanxi Medical University · CN

Funding

Natural Science Foundation of ShanXi Province in China 201901D211498Youth Science foundation of Second Hospital of ShanXi Medical University in China 201902-1
6 · The paper itself

Abstract

backgroundPancreatic cancer has been a threateningly lethal malignant tumor worldwide. Despite the promising survival improvement in other cancer types attributing to the fast development of molecular precise medicine, the current treatment situation of pancreatic cancer is still woefully challenging since its limited response to neither traditional radiotherapy and chemotherapy nor emerging immunotherapy. The study is to explore potential responsible genes during the development of pancreatic cancer, thus identifying promising gene indicators and probable drug targets.

methodsDifferent bioinformatic analysis were used to interpret the genetic events in pancreatic cancer development. Firstly, based on multiple cDNA microarray profiles from Gene Expression Omnibus (GEO) database, the genes with differently mRNA expression in cancer comparing to normal pancreatic tissues were identified, followed by being grouped based on the difference level. Then, GO and KEGG were performed to separately interpret the multiple groups of genes, and further Kaplan-Meier survival and Cox Regression analysis assisted us to scale down the candidate genes and select the potential key genes. Further, the basic physicochemical properties, the association with immune cells infiltration, mutation or other types variations besides expression gap in pancreatic cancer comparing to normal tissues of the selected key genes were analyzed. Moreover, the aberrant changed expression of key genes was validated by immunohistochemistry (IHC) experiment using local hospital tissue microarray samples and the clinical significance was explored based on TCGA clinical data.

resultsFirstly, a total of 22,491 genes were identified to express differently in cancer comparing to normal pancreatic tissues based on 5 cDNA expression profiles, and the difference of 487/22491 genes was over eightfold, and 55/487 genes were shared in multi profiles. Moreover, after genes interpretation which showed the > eightfold genes were mainly related to extracellular matrix structural constituent regulation, Kaplan-Meier survival and Cox-regression analysis were performed continually, and the result indicated that of the 55 extracellular locating genes, GPRC5A and IMUP were the only two independent prognostic indicators of pancreatic cancer. Further, detailed information of IMUP and GPRC5A were analyzed including their physicochemical properties, their expression and variation ratio and their association with immune cells infiltration in cancer, as well as the probable signaling pathways of genes regulation on pancreatic cancer development. Lastly, local IHC experiment performed on PAAD tissue array which was produced with 62 local hospital patients samples confirmed that GPRC5A and IMUP were abnormally up-regulated in pancreatic cancer, which directly associated with worse patients both overall (OS) and recurrence free survival (RFS).

conclusionsUsing multiple bioinformatic analysis as well as local hospital samples validation, we revealed that GPRC5A and IMUP expression were abnormally up-regulated in pancreatic cancer which associated statistical significantly with patients survival, and the genes' biological features and clinical significance were also explored. However, more detailed experiments and clinical trials are obligatory to support their further potential drug-target role in clinical medical treatment.

Indexed as

Bioinformatic analysisGEO databaseGPRC5A geneIMUP geneIndependent survival indicatorMolecular pathologyPancreatic cancer

Identifiers

PMID34819098
PMCPMC8613923
OpenAlexW3198914829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.